Premium
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus‐like‐particle vaccine in Latin American women
Author(s) -
Perez Gonzalo,
LazcanoPonce Eduardo,
HernandezAvila Mauricio,
García Patricia J.,
Muñoz Nubia,
Villa Luisa L.,
Bryan Janine,
Taddeo Frank J.,
Lu Shuang,
Esser Mark T.,
Vuocolo Scott,
Sattler Carlos,
Barr Eliav
Publication year - 2007
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.23260
Subject(s) - medicine , vaccination , immunogenicity , latin americans , genital warts , population , cervical cancer , placebo , gynecology , immunization , immunology , virology , antibody , cancer , environmental health , pathology , linguistics , philosophy , alternative medicine
The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virus‐like‐particle vaccine has been shown to be 95–100% effective in preventing HPV 6/11/16/18‐related cervical and genital disease in women naïve to vaccine HPV types. A total of 6,004 female subjects aged 9–24 were recruited from Brazil, Mexico, Colombia, Costa Rica, Guatemala and Peru. Subjects were randomized to immunization with intramuscular (deltoid) injections of HPV vaccine or placebo at enrollment (day 1), month 2 and month 6. Among vaccinated subjects in the per‐protocol population from Latin America, quadrivalent HPV vaccine was 92.8 and 100% effective in preventing cervical intraepithelial neoplasia and external genital lesions related to vaccine HPV types, respectively. These data support vaccination of adolescents and young adults in the region, which is expected to greatly reduce the burden of cervical and genital cancers, precancers and genital warts. © 2007 Wiley‐Liss, Inc.